IAVI and BARDA expand partnership to advance IAVI’s filovirus vaccine candidates
March 1, 2023
Funding will allow for additional development and testing of IAVI’s single-dose vaccine candidates against the filoviruses Marburg virus and Sudan ebolavirus.
The Netherlands renews their support to IAVI for the development of new HIV prevention technologies
February 22, 2023
The Ministry will award IAVI €21 million over the next five years as part of the Product Development Partnership IV Fund.
Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach
December 2, 2022
Scripps Research, IAVI, Fred Hutch, VRC and other collaborators publish study data in Science, helping validate novel vaccination strategy.
IAVI to accelerate promising investigational Sudan ebolavirus vaccine development for potential outbreak research and response
October 25, 2022
Merck will provide the investigational vaccine based on a proven platform technology.
IAVI announces first vaccinations at Liberia site in Phase 1 clinical trial of Lassa fever vaccine candidate
August 31, 2022
The trial is designed to evaluate the candidate’s safety, tolerability, and immunogenicity.
Japan reiterates commitment to HIV vaccine development with a $10.5 million contribution to IAVI
August 29, 2022
NEW YORK, NY — AUGUST 29, 2022 — The Government of Japan announced at the occasion of the Eighth Tokyo International Conference on African Development (TICAD8) held in Tunisia on August 27 and 28, 2022, its commitment to contribute US$10.5 million to IAVI’s VSV-HIV vaccine development program over the next five years. This funding will…
IAVI and Moderna launch first-in-Africa clinical trial of mRNA HIV vaccine development program
May 18, 2022
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity.